Blogs

Two debates anticipated for #SABCS21

colesColes

JuliaWhite2White

Michael_Gnant_MedUni...Gnant

loibl-sibylle-d80733...Loibl

Debate has been described as an intellectual sport. The debaters are the contestants pitting their research ability, critical thinking, and argument skills against one another to make their point.

Attendees of this year’s San Antonio Breast Cancer Symposium will have two opportunities to watch experts debate the pros and cons related to two breast cancer treatments.

Thursday, Dec. 9 at 11:30 a.m., Charlotte E. Coles, PhD, of the University of Cambridge in the United Kingdom, will debate Julia White, MD of The Ohio State University in Columbus, Ohio. The topic will be, “One Week of Whole Breast RT Is the New Standard of Care.” Coles will argue for the pro stance and White, against.

The next debate will be Friday, Dec. 10 at 11:30 a.m. Michael Gnant, MD of Medical University of Vienna in Austria will debate Prof. Dr. Sibylle Loibl, of GBG Forschungs GMBH in Hessen, Germany. Their topic will be, “RxPONDER: Was It all OFS?” Gnant will argue “yes” while Loibl will argue, “no.”

Virtual attendants will be able to participate live or watch later. Those attending in person can see the debates in Hall 3. The audience will be polled regarding their position on each topic at the start of the debate. They will be polled again at the end to see which participant was most persuasive in their arguments.

Registration is open for #SABCS21 at the Henry B. Gonzalez Convention Center, Dec. 7–10. It will be a hybrid conference with in-person and virtual attendance for all sessions. Everyone attending in person is required to wear a mask.

Discounted registration is available through Oct. 31. Visit SABCS.org to register, book a hotel, or get more information.

 

Categories: Program | Tags: San Antonio Breast Cancer Symposium, #SABCS21, Charlotte E. Coles, Julia White, Michael Gnant, Sibylle Loibl, University of Cambridge, The Ohio State University, Medical University of Vienna, GBG Forschungs GMBH, RxPONDER | View Count: (357) | Return

Post a Comment